Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742387 · ClinicalTrials.gov registry record
Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
A clinical trial of Kaposi Sarcoma and Primary Effusion Lymphoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT04742387 is a study of Kaposi Sarcoma and Primary Effusion Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 99-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04742387, a study of Kaposi Sarcoma and Primary Effusion Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Some people with human immunodeficiency virus (HIV) are on antiretroviral therapy (ART). Their cells have shown to age faster than expected. This puts them at higher risk for a range of age-related diseases about 10 years sooner than people who do not have HIV. Low bone mineral density (BMD) is common in people with HIV. This means their risk of fractures is increased. People with HIV also have a higher risk for cancers caused by Kaposi's sarcoma herpesvirus (KSHV) than people who do not have HIV. Much of the data on bone loss related to cancer and cancer treatments has been gathered from people who do not have HIV. Researchers want to learn more about the rate of bone loss in people with HIV/AIDS and KSHV associated cancers. Objective: To learn the factors that are linked to BMD loss in people with HIV and KSHV associated cancers from imaging performed as part of NIH studies. Eligibility: Adults with HIV and Kaposi s sarcoma who got ART and cancer chemotherapy at NIH from 1/1/2005 to 12/1/2020. Design: Participants' records will be chosen from studies that were conducted from 1/1/2005 to 12/1/2020. This study will include participants who had at least 2 CT scans. Some participants may have opted out of the future use of their data. If so, their records will not be used. This study will use data collected at NIH. Data taken from CT scans will be used to measure BMD. Study results may be published. This study will last about 2 years.
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04742387
The ClinicalTrials.gov registry entry for NCT04742387 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (60% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Kaposi Sarcoma appearing as the primary indexed condition, and to 0 interventions.
NCT04742387 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04742387 about?
NCT04742387 is a clinical study titled "Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis". Background: Some people with human immunodeficiency virus (HIV) are on antiretroviral therapy (ART). Their cells have shown to age faster than expected. This puts them at higher risk for a range of age-related diseases about 10 years sooner than people who do not have HIV. Low bone mineral density ...
What is the current status of trial NCT04742387?
This trial is currently active not recruiting. The enrollment target is 40 participants. The study started on 2021-02-04. Estimated completion is 2027-12-31.
What conditions does trial NCT04742387 study?
This clinical trial studies the following conditions: Kaposi Sarcoma, Primary Effusion Lymphoma, KSHV Associated Multicentric Castleman Disease, IL-6 Related KSHV Associated Cytokine Syndrome.
Who is sponsoring clinical trial NCT04742387?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04742387 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RECRUITING · Phase 1
-
Trial of Ixazomib for Kaposi Sarcoma
RECRUITING · Phase 2
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RECRUITING · Phase 1
-
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
RECRUITING · Phase 2
-
A Study of sEphB4-HSA in Kaposi Sarcoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.